2014
Intravitreal injection of bevacizumab for retinopathy of prematurity
Japanese Journal of Ophthalmology
- ,
- ,
- ,
- ,
- ,
- Volume
- 58
- Number
- 3
- First page
- 237
- Last page
- 243
- Language
- English
- Publishing type
- Research paper (scientific journal)
- DOI
- 10.1007/s10384-014-0310-z
- Publisher
- Springer-Verlag Tokyo
Purpose: To evaluate the outcomes of intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP). Methods: IVB was selected to be the first treatment for type 1 ROP in 8 eyes (4 patients). Bevacizumab (0.25 mg/eye) was injected into the vitreous cavity under either general anesthesia or sedation. Fundus photography and fluorescein angiography were performed before the IVB. One infant was observed to the age of 1 year 6 months, the second to 1 year 9 months, the third to 1 year 10 months, and the fourth to 2 years 0 month. Results: Before the IVB, 6 eyes (3 patients) had ROP in zone II and 2 eyes (one patient) had ROP in zone I. The 3 infants with ROP in zone II weighed 652, 476, and 579 g with gestational ages of 24, 27, and 24 weeks at birth, respectively. The infant with ROP in zone I weighed 972 g with a gestational age of 26 weeks at birth. IVB was performed at postmenstrual ages of 33-37 weeks. The IVB was effective in all eyes with ROP in zone II and additional treatment was not required, whereas vitreous hemorrhage and cataract were found at 19 weeks and 5 months after the initial IVB in the two eyes with ROP in zone I. These two eyes required additional IVB, laser photocoagulation, and surgery. Conclusions: Our findings suggest that eyes with type 1 ROP in zone II can be treated with IVB. Further studies are needed with a larger number of eyes. © 2014 Japanese Ophthalmological Society.
- Link information
- ID information
-
- DOI : 10.1007/s10384-014-0310-z
- ISSN : 1613-2246
- ISSN : 0021-5155
- Pubmed ID : 24566819
- SCOPUS ID : 84900799899